SPECIAL SUMMER SEMINAR- From Bench to Bedside... and Back to Bench

Tarih: 21.07.2014
Yer: Sabanci University, Nanotechnology Research and Application Center (SUNUM), Room G111

Philipp Jungebluth, M.D., Ph.D.

Advanced Center for Translational Regenerative Medicine,

Karolinska Institutet, Stockholm, Sweden


End-stage organ failure is one of the major challenges for medicine and this can worsen due to demographic changes. Despite enormous efforts in medical and basic research, allogeneic organ transplantation is probably the only curable treatment option for these patients. However, the growing shortage of donor organs and the need for lifelong immunosuppression with its associated morbidity are some requirements for novel therapeutic option. Tissue engineering (TE) is becoming a very promising alternative. Early clinical applications have demonstrated the feasibility of using TE to replace damaged tissue and organs with rather simple architecture. Preclinical findings also suggest that even higher complex organs can be successfully engineered and transferred to the clinic in the near future. Basic components of the tissue engineering concept include i) a scaffold ii) cells iii) a bioreactor and iv) pharmaceutical intervention/bioactive molecules. We were recently successful in performing the first-in-man tissue engineered tracheal transplantation using either biological or artificial scaffolds, patient’s own bone marrow derived stem cells, and bioactive molecules. Lessons learnt from the bench-to-bedside research activities include positive and negative patient’s long-term results, cross-interaction of cells and neighboring tissues, circulating stem/progenitor cells and mathematical modeling approaches for understanding and predicting regeneration. Can we transfer the model to other more complex organs? Although the feasibility of a concept with great potential was demonstrated, further efforts must be done to elucidate underlying pathways and mechanisms. Only continuous evaluations and re-investigations of the already clinically applied methodology can provide stronger evidence to transfer the concept into clinical routine.



If you wish to arrange a one-to-one meeting with Dr. Jungebluth, please contact tolgasutlu@sabanciuniv.edu

Selected publications:

Gonfiotti A. et al. The first tissue-engineered airway transplantation: 5-year follow-up results.
Lancet. 2014 Jan18;383(9913):238-44. PMID: 24161821.

Jungebluth P. et al. Verification of cell viability in bioengineered tissues and organs before clinical transplantation.
Biomaterials. 2013 May;34(16):4057-67. PMID: 23473965.

Lim M.L. et al. Whole organ and tissue reconstruction in thoracic regenerative surgery.
Mayo Clin Proc. 2013 Oct;88(10):1151-66. PMID: 24079685.

Jungebluth P. et al. The concept of in vivo airway tissue engineering.
Biomaterials. 2012 Jun;33(17):4319-26.PMID: 22440048.

Jungebluth P. et al.Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
Lancet. 2011 Dec10;378(9808):1997-2004. PMID: 22119609